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Linda C. Duffy, Ph.D., Robert C. Welliver, M.D., Maria A. Zielezny, Ph.D., Joseph T. DiPiro, Pharm.D., 
Marsha A. Raebel, Pharm.D., and Thaddeus H. Grasela, Pharm.D. 
We conducted a prospective surveillance study of 80 hospitals across the United 
States to determine the incidence of sepsis syndrome and its associated sequelae 
in hospitalized patients over age 18 years who were administered antibiotics for 
suspected or documented gram-negative infection. A sample of 1754 
hospitalized patients were followed from onset of antimicrobial therapy to 
discharge or death. Mortality rates (MR) varied depending on the suspected 
source of sepsis syndrome. For patients in whom the syndrome was associated 
with community-acquired urinary tract infections, mortality was 20% (relative 
risk [RR] = 0.51, p<0.05), for those with trauma 20.6% (RR = 0.51, p<0.05), and 
patients with nosocomial respiratory tract infections 57.1% (RR = 1.66, p<0.05). 
More than two complications occurred in 65.2% of patients under age 60 years 
(MR 31%), 40.8% of those age 60-80 (MR 42%), and 35.6% of patients older 
than 80 years (MR 33.3%, p>0.05). Various patient populations had significant 
differences in both the incidence of the syndrome and its complications, and 
consequent mortality Perhaps morbidity as well as mortality should be used as 
outcomes when testing the efficacy of innovative therapies for sepsis. 
(Pharmacotherapy 1995; 1% 1): 66-77) 
In the United States i t  is estimated that 
100,000-300,000 hospitalized patients develop 
septicemia each year, with an associated mortality 
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rate of 20-50%.', ' Sepsis is currently the most 
common cause of death in the intensive care u n i ~ . ~ , ~  
As the use of advanced life support  systems 
increases, and the population ages and becomes 
more severely il l ,  we are faced with an ever 
growing number of individuals at risk for this 
devastating syndrome. 
It is well recognized that the incidence of sepsis 
and its associated sequelae vary among patient 
populations. Those reported to be at high risk for 
sepsis include the elderly, and critically ill andlor 
immunosuppressed patients,', 3 ,  4-6 but comparative 
information in other high-risk populations is 
lacking, Identifylng such patients is an important 
first step to enhancing our understanding of the 
evolution of this complex disease process. This 
information will assist in pinpointing population- 
specific risk factors for complications and 
mortality, allow refining of treatment algorithms, 
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and aid in developing cost-effective strategies to 
lessen the financial burden of new therapies on the 
health care system. 
Methods 
Our overall goal was to develop a descriptive 
data base of the natural history of sepsis and 
complications resulting from suspected or 
documented gram-negative infections in selected 
high-risk patient populations. 
Subjects and Design 
This study was performed using the nationwide 
Drug Surveillance Network7 of clinical pharmacists 
organized to conduct surveillance studies of 
hospitalized patients. Data were collected at 80 
hospitals across the United States and Canada, 
65% of which were affiliated with a medical 
school. The hospitals ranged in size from 48-941 
beds [mean (SD) 391 (213) beds]. The mean (SD) 
bed size for medical school-affiliated hospitals was 
480 (2041, and for nonmedical school-affiliated 
hospitals 249 (149). 
To identify patients with a high incidence of 
gram-negative sepsis, certain populations were 
targeted. Specifically, patients were enrolled in the 
study if antibiotic therapy was initiated for 
suspected or documented gram-negative infection 
and they had at least one of the following 
presumed sources of infection: documented 
intraabdominal infection (abscess, gangrenous or 
necrotic organs, peritonitis); suspected or 
documented gram-negative or mixed skin flora 
infections and systemic signs of infection such as 
fever (temperature > 38.3’0 and elevated white 
blood cell count (> 10,500/mm3); cancer with an 
absolute neutrophil count less than 1000 cells/mm3 
and temperature above 38.3”C; multiple trauma 
expected to require intensive care unit (ICU) 
treatment for longer than 3 days; documented 
gram-negative bacteremia with or without an 
identifiable source; suspected or documented 
gram-negative urinary tract infection acquired in 
the community, hospital, or nursing home, and 65 
years of age or greater; or suspected or 
documented gram-negative respiratory tract 
infection acquired in the hospital or nursing home, 
and 65 years of age or greater. Based on these 
inclusion criteria, patients were classified into the 
following populations: urinary tract infection 
acquired in the community, nursing home, or 
hospital; respiratory tract infection acquired in a 
nursing home or hospital; intraabdominal 
infection; skin infection; multiple trauma; febrile 
neutropenic cancer; and documented gram- 
negative bacteremia with or without an identifiable 
source of infection and mutually exclusive of other 
patient populations. 
Patients were excluded from participation if they 
were less than 18 years of age or had one of the 
following: fungal, viral, or gram-positive infection 
as documented by culture without evidence of 
concurrent gram-negative infection; suspected or 
documented gram-positive skin infection, 
including cellulitis, wound infection, and fasciitis; 
organ transplantation during the current 
hospitalization; presence of human immuno- 
deficiency virus; obstetric-gynecologic infection; or 
experimental therapy with antiendotoxin 
monoclonal antibodies. Patients with only one of 
the following were also excluded: uncomplicated 
diagnosis of cholecystitis, acute appendicitis, 
pancreatitis, or acute perforated peptic ulcer; 
diverticulitis without abscess or peritonitis; 
peritonitis associated with peritoneal dialysis; 
intravenous or intraarterial catheter-related 
infection; uncomplicated diagnosis of upper 
respiratory tract infection; or prostatitis. These 
exclusion criteria were developed as guidelines for 
patient selection, thus decreasing the variability of 
diagnostic criteria by the investigator. Patients 
classified as “do not resuscitate” at study entry were 
excluded. 
To minimize sampling bias, two sampling 
strategies were used. In the first strategy, clinical 
pharmacists identified all patients in the hospital 
who met particular inclusion criteria (e.g., all 
febrile neutropenic patients with cancer, all those 
with multiple trauma) and enrolled them 
consecutively. In the alternative strategy, subjects 
were enrolled using the entire hospital patient 
population as a basis for recruitment. Because the 
latter would likely result in a large number of 
simultaneously eligible patients, each site selected 
one or more days per week for routine screening. 
On the preselected day(s), all eligible patients ( e g ,  
those started on antibiotics for suspected gram- 
negative infection) were identified. The maximum 
number of patients to be enrolled on a screening 
day was determined before the start of data 
collection. To ensure that patients were 
systematically enrolled, the order of their entry was 
based on the last four digits of the hospital 
identification number in ascending order until the 
maximum number was achieved. 
All data were recorded on a form specifically 
designed for the study The form recorded patient 
demographics and comorbidities; antibiotic 
regimens; vital signs, hemodynamic monitoring, 
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Table 1.  Definitions of Events 
Event Definition 
Sepsis syndrome Temperature 2 38 3°C or < 35 6"C, tachycardia 2 90 bpm, tachypnea 2 20 bpm, evidence of decreased 
organ perfusion as measured by one of the following changes in mental status, PaOl/FI02 < 280, 
elevated plasma lactate level, urinary output < 0 5 mVkg8 
Complication Definition Resolution 
Refractory shock Systolic BP < 90 mm Hg or ( in a hypertensive Systolic BP > 90 mm Hg or (in a hypertensive patient) 
patient) 2 40-rnm Hg decrease, neither 
responsive to i.v. fluids or vasopressors. 
2 40-mm Hg increase, both without vasopressor 
support. 
Adult respiratory 
Acute renal failure 
distress syndrome 










PaO2/F1O2 < 175 bilateral pulmonary infiltrates 
on chest film, and/or PCWP < 18 mm Hg ' 
Serum creatinine increases to 2 176 pmoVL 
Serum creatinine greater than normal (> 132 
pmoVL) and BUN greater than normal 
(> 78.9 umoVL) with both rising for several 
days, or patients with new onset of dialysis. 
Elevated fibrin degradation products (FDP) 
titer > 1:40 or D-Dimers > 2.0 in conjunction 
w t h  decrease > 25% of baseline in platelet 
count and either an elevated PT or PTT, or 
clinical evidence of bleeding.* 
and either an elevated PT or PTT, or clinical 
evidence of bleeding. 
Bilirubin > 34 pmoVL; alkaline phosphatase, 
y-glutamyl transpeptidase, aspartate amino- 
transferase, or alanine aminotransferase 
exceeded twice the upper limit of normal.* 
Decrease > 25% of baseline in platelet count 
Glasgow Coma Scale < 15 or 1 Doint lower than a 
Clearing of bilateral lung infiltrates and Pa02/FI02 
> 175. 
Serum creatinine returned to < 176 pmoVL or baseline 
in patients with preexisting renal insufficiency. 
Serum creatinine returned to < 132 pmoVL 
D-Dimers < 2 0, FDP < 1 40, PT or PTT returned to 
normal, and platelets increased by 25% over nadir 
and returned to normal 
I 
PT or PTT returned to normal, and platelets increased 
by 25% over nadir and returned to normal 
Bilirubin < 34 pmoVL, and confirming enzyme 
abnormality resolved. 
GCS returned to IS or baseline 
system dysfunction basuline GCS, physician judgment of change 
in mental status. 
Pa01 = partial pressure of oxygen; FIOr = fractional concentration of inspired oxygen; PCWP = pulmonary capillary wedge pressure; BUN = blood 
urea nitrogen; PT = prothrombin time; PTT = partial thromboplastin time 
At the time this study was initiated the new definitions proposed by ACCP-SCCM were not published. 
ventilation status, serum chemistries, hematology 
blood transfusions, blood gases; microbiology with 
results of cultures and susceptibilities; concomitant 
drugs including vasopressors and fluids; and 
patient status at discharge. This information was 
recorded on a daily basis. In addition, the 
following information was obtained to document 
inadequate organ function or perfusion: alteration 
in mental status as measured by Glasgow Coma 
Score or clinician evaluation; hypoxemia with a 
partial pressure of oxygen (PaOz) below 75 torr 
breathing room air in the absence of severe lung 
disease; increased plasma lactate concentration (> 2 
mmol/L or above the upper limits for the 
laboratory); and oliguria (urine output < 30 mVhr). 
Renal failure, adult respiratory distress 
syndrome, disseminated intravascular coagulation, 
liver dysfunction, and central nervous system 
dysfunction were specifically targeted as potential 
complications associated with sepsis, and are 
reported as such. Refractory shock was not 
reported as a complication, but as a separate entity 
Specific information was collected regarding the 
date of onset, severity, treatment modalities, 
duration, and outcome for each complication. 
Clinical pharmacists evaluated each patient on a 
daily basis and made an assessment as to whether 
or not the patient had sepsis syndrome and its 
associated complications based on the clinical 
impressions of the medical team and objective 
clinical data. To minimize bias, the clinical 
pharmacists were provided standard definitions for 
sepsis and its complications (Table 1). When we 
started this protocol, sepsis syndrome was the 
definition in current use. However, enough data 
were collected to look at new  definition^.^ 
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On receipt a t  the research center, case report 
forms were reviewed for completeness and 
consistency. When necessary, participants were 
contacted to provide missing information or to 
clarify data entries or  omissions. A toll-free 
telephone number was maintained to facilitate 
communication and resolve study questions. A 
10% random sample of each institution’s patient 
discharge summaries was collected and compared 
with the case report forms for quality assurance 
purposes. All patients were monitored from the 
time of initiation of antimicrobial therapy for the 
infectious episode until discharge or death, or for a 
minimum of 14 days. 
All laboratory studies, patient care procedures, 
diagnostic procedures, and drug therapy decisions 
were performed according to the usual clinical 
practice a t  the participating institutions. On 
identification of an eligible patient,  only 
information available in the medical record was 
collected, and no changes in patient care were 
required for the purposes of this survey The only 
risk to patients was a breach of confidentiality, and 
safeguards were implemented to protect their 
identity. Clinical pharmacists were required to 
follow federal and institutional guidelines that 
govern participation in observational research. 
Statistical Analysis 
The primary end points for this analysis were the 
development of signs and symptoms of sepsis 
syndrome, development of refractory shock, 
specific complications including adult respiratory 
distress syndrome, acute renal failure, disseminated 
intravascular coagulation, hepatobiliary dysfunction, 
central nervous system dysfunction, and mortality. 
A data base was created using a dBase 111 plus 
(Borland International Inc., Scotts Valley, CA) 
application and was analyzed using the SAS (SAS 
Institute Inc . ,  Cary, NC) statistical package. 
Double entry of data was performed to ensure 
accuracy. The incidences of sepsis syndrome, 
refractory shock, and complications were 
determined for the overall patient population and 
within each subpopulation. An interim analysis 
showed a high recruitment of patients with 
community-acquired urinary tract infections and 
skin infections, and a low incidence of sepsis 
syndrome; hence recruitment into these 
populations was terminated early Therefore, the 
relative proportion of patients within each patient 
population should be interpreted cautiously 
Summary statistics of demographics were 
reported for all patients. x2 tests were used to 
determine differences in the incidence of end 
points among patient populations. The following 
demographics were compared between patients 
within a population with those of all other patients 
using the x2  test: gender, surgery during study 
enrollment, outpatient antibiotic use, source of 
infection, and type of organism. Student’s t test 
was employed to compare the subpopulation with 
all other patients with regard to age, time from 
admission to sepsis, hospital duration, ICU stay, 
and number of comorbidities. Relative risk (RR) of 
mortality was calculated as the incidence rate 
among those patients in a specific population 
divided by the incidence rate in all other patient 
populations. Statistical significance was defined as 
p below 0.05. 
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Figure 1.  Number of comorbidities stratified by mortality. 
For all 1754 patients comorbidities included chronic 
obstructive pulmonary disease, congestive heart failure, stroke 
or cerebral hemorrhage, diabetes mellitus, hepatic disease, 
malignancy, renal disease, major burn,  and history of 
alcoholism. 
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Table 2. Incidence of Complications 
Patients With Sepsis Syndrome 
With Refractory 
All Patients A11 Patients Shock Mortality 
(n = 1754) (n = 457) (n = 216) 
No. (%) No. (%) No. (%) No. (%)a  
Refractory shock 216 (47.3) 116 (53.7) 
Adult respiratory distress syndrome 85 (4.8) 82 (17.9) 57 (26.4) 39 (47.6) 
Acute renal failure 75 (4 3) 65 (14.2) 47 (21 8) 39 (60.0) 
Acute renal failure wthout baseline data 48 (2.7) 44 (9.6) 36 (16.7) 31 (70.5) 
Disseminated intravascular coagulopathy 37 (2.1) 35 (7.7) 30 (13 9) 27 (77.1) 
Coagulopath y 51 (2.9) 49 (10.7) 38 (17.6) 25 (51.0) 
Hepatobiliary dysfunction 79 (4.5) 75 (16.4) 53 (24.5) 36 (48.0) 
Central nervous system dysfunction 151 (8.6) 146 (31.Y) 95 (44.0) 81 (55.5) 
'Denominator = number of patients with sepsis syndrome m that complication category. 
Results 
Overall Patient Population 
A total of 1754 patients were enrolled, of whom 
889 (50.7%) were men. The mean (SD) age was 
67 (18.4) years (range 18-110 yrs). The majority 
of patients (1188, 67.7%) were admitted from the 
community, 427 (24.3%) from a nursing home or 
long-term care facility, and 136 (7.8%) from 
another hospital. On admission, 12.8% of patients 
were admitted directly to an ICU, and another 
26.9% were admitted to the ICU at some time later 
in their hospitalization. Of the 1754 patients, 74% 
were admitted to a medical service, 25% to a 
surgical service, and 1% unknown. Figure 1 shows 
comorbidities of all patients and their relationship 
to discharge or death. The patients who died had a 
mean (SD) of 1.5 (0.99) comorbidities, and those 
who were discharged had 1.1 (1.07) comorbidities, 
which was statistically significant (p<O.OOO 1). 
Overall, 389 (22.2%) had gram-negative 
bacteremia; 457 (26.1%) had sepsis syndrome, 216 
(47.3%) of whom developed refractory shock. The 
mortality rates were 14.5%, 37.6%, and 53.7% for 
all patients, those with sepsis syndrome, and 
patients with refractory shock, respectively. The 
relative risk of death in patients with sepsis 
syndrome compared with patients without the 
syndrome was 5.97 (p<O.OOOl). The relative risk 
of death in patients with sepsis syndrome and 
refractory shock compared with patients with 
sepsis syndrome and no refractory shock was 2.3 
The incidence of complications was significantly 
greater in patients with sepsis syndrome who had 
refractory shock than in those without shock 
(p<O.OOl; Table 2). It ranged from a low of 7.7% 
for disseminated intravascular coagulation to a 
(p<0.0001). 
high of 3 1 . 9 %  for central nervous system 
dysfunction. Mortality was highest for patients 
with disseminated intravascular coagulation 
(77.1%). Of the 457 patients with sepsis syndrome, 
no complications developdd in 37.4%, one compli- 
cation in 34.1%, two in 16.2%, three in %.7%, four 
in 1.8%, and five in 1.8%; their respective mortality 
rates were 15.8%, 43.0%, 55.4%, 65.0%, 50.0%, 
and 87.5%. 
Sepsis syndrome developed in 120 (26.3%) of 
patients less than 60 years of age, 250 (54.7%) of 
those age 60-80 years, and 87 (19.0%) of patients 
older than 80 years. For these three age groups, 
93 .3%,  74 .8%,  and 52.9% were in  the ICU 
(p<O.OOl). Patients with sepsis syndrome and less 
than 60 years of age were more likely to be in the 
ICU for more than 9 days than those in the other 
age groups, 53.6%, 33.7%, 21.7%, respectively, 
(p<O.OOl). Two or more complications occurred in 
62.5% of patients with sepsis syndrome who were 
less than 60 years of age, 40.8% of those 60-80 
years of age, and 35.6% of those older than 80 
years. Mortality rates for the patients with sepsis 
syndrome in the three age groups were 31.0%, 
42%,  and 33.3%, respectively (p>O.OS). In 
patients without sepsis syndrome, the rates were 
1.3%, 7.4%, 9.2%, respectively (p<O.OOl). 
Of the 389 patients with gram-negative 
bacteremia, the suspected sources of organisms 
were the urinary tract 41.4%, unknown 17.5%, 
intraabdominal 15.4%, several possible sources 
1 0 . 8 % ,  respiratory tract 10.0%, skin 2.8%, 
intravascular catheter 1.8%, and other sources 
0.6%. The suspected sources of gram-negative 
bacteremia for the subset of 164 patients with 
sepsis syndrome were the urinary tract 37.6%, 
several possible sources 16.7%, intraabdominal 
15.4%, respiratory tract 13.6%, unknown 13%, 
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intravascular catheter 1.9%, skin l.2%, and other 
sources 0.6%. Patients with a lower respiratory 
tract infection and those with several possible 
sources of bacteremia were significantly more likely 
to develop sepsis syndrome than those with other 
sources. In contrast, patients who had a skin or an 
unknown source of bacteremia were significantly 
less likely to develop sepsis (p<0.05). 
The specific gram-negative organisms cultured 
from blood were not significantly different in 
patients with and without sepsis syndrome 
(p>0.05; Figure 2). Patients with Enterobacter sp 
(E. cloacae, E. aerogenes, E. agglornerans) isolated 
from their blood had a high mortality rate (34.5%, 
RR = 2.00, p<O.Ol) as did those with Pseudornonas 
sp (P aeruginosa, l? cepacia; 34.8%, RR = 2.13, 
p<O.Ol) compared with patients with other 
isolates. In contrast, patients with Escherichia coli 
had a mortality rate of 9.7% (RR = 0.40, p<O.Ol), 
which was significantly lower than that in patients 
with other gram-negative isolates. In the subset of 
patients with sepsis syndrome, with the exception 
of those with E. coli, who had a lower risk of death, 
the bacterial isolate did not influence mortality. 
Table 3 shows the 10 most common isolates and 
their sources. Staphylococcus sp were isolated from 
10.6% of blood cultures (MR 23.5%), Staphylococcus 
aureus from 3.6% (MR 30.7%), and Candida 
albicans from 0.6% (MR 66.7%). Overall, 20% of 
patients had no positive cultures (MR 9.1 %), 34% 
had one positive culture (MR 10.9%), 20.4% had 
two positive cultures (MR 15.7%), 11.5% had 
three positive cultures (MR 21.9%), 6.7% had four 
positive cultures (MR 16.1%), 4.7% had five 
positive cultures (MR 31.3%), 1.8% had six 
positive cultures (MR 19.4%), and 1% had seven 
or more positive cultures (MR 35.3%). 
The mean (SD) duration of hospital stay for all 
patients was 18 (17.8) days. Mean (SD) overall 
antibiotic duration was 14.3 (11.2) days. As 
required for study enrollment, all patients received 
antibiotics; however, the agents administered 
varied greatly. Overall, patients received a total of 
605 different combinations of antibiotic classes 
during the course of this study. The most 
commonly prescribed regimens for patients with 
sepsis syndrome were third-generation cephalo- 
sporins, penicillins, aminoglycosides plus a third- 
generation cephalosporin, aminoglycoside plus a 
penicillin, and imipenem. Specific evaluation of 
individual regimens and their impact on outcome 
will be the subjects of future reports. 
Subset Analysis 
Patient populations varied widely in a number of 
E. CoU 
Figure 2 .  Frequency of gram-negative blood isolates (n=389). Miscellaneous = a gram-negative blood isolate not listed above; 
mixed = more than one gram-negative organism isolated. 
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Table 3. Organisms Stratified by Site of Culture 
Organism No. (%) No. (%) No. (%) No. (%) No. (%) No. (Oh) 
Escherichia coli 185 (17 1) 257 (25.2) 26 (5.3) 15 (19 7) 130 (21.0) 613 (34.9) 
Pseudomonus aeruginosu 54 (5.0) 87 (8.5) 112 (22.9) 14 (18.4) 100 (16.1) 367 (20.9) 
Sluphylococcus sp 115 (10.6) 28 (2.7) 38 (7.8) 14 (18.4) 98 (15.8) 293 (16 7) 
Enterococcus sp 25 (2.3) 105 (10.3) 31 (6.3) 11 (1q.5) 79 (12.7) 252 (14.4) 
Klebsiella pneumoniae 67 (6.2) 74 (7.3) 45 (9.2) 5 (6.6) 56 (9.0) 248 (14 1) 
Staphylococcus aureus 39 (3.6) 8 (0.8) 72 (14.7) 13 (17.1) 82 (13.2) 214 (12.2) 
Enterobacter- claacur 24 (2.2) 20 (2.0) 42 (8.6) 3 (3.9) 83 (13.4) 172 (9.8) 
Gram-negative sp 38 (3.5) 33 (3.2) 33 (6.7) 3 (3.9) 33 (5.3) 140 (8.0) 
Proteus mirabilis 22 (2.0) 56 (5.5) 13 (2.7) 10 (13.2) 25 (4.0) 127 (7.2) 
Candida ulbicans 6 (0.6) 40 (3.9) 27 (5.5) 3 (3.9) 27 (4.4) 104 (5.9) 
Denominators for percentages are total number of patients with a culture for that site. blood = 1081, urine = 1020, sputum = 490, wound = ‘76, 
other = 620, all = 1754. 
Blood Urine Sputum Wound Other All 
demographic variables (Table 4). Most patients 
(74%) were admitted to the medical service, except 
for trauma patients who were all admitted to the 
surgical service. Sixty percent of patients with 
intraabdominal infection were also admitted to the 
surgical service. The mean (SD) age of patients, 
excluding the populations restricted to ages greater 
than 65  (community-acquired urinary tract 
infection, nursing home-acquired urinary tract and 
respiratory tract infections, nosocomial urinary 
tract and respiratory tract infections), was 54.8 
(18.8) years. In this group, 53.3% were women, 
whereas of all patients less than 50 years of age, 
58.2% were men. Also, the time to onset of sepsis 
was significantly different in the patient 
populations. Of the 152 patients admitted to the 
hospital with sepsis already, 48% had nursing 
home-acquired infections. Patients with 
community-acquired urinary tract infections had 
the shortest antibiotic treatment and hospital stay, 
and were most likely to be discharged taking 
antibiotics, 47% versus 26 .4% of all other 
populations (p<O.OO 1). Other significant events 
that have been reported to affect a patient’s risk of 
sepsis, as well as mortality, are ICU stay and 
performance of surgical procedures. 
Patients spending the most time [mean (SD) 
days] in the ICU before the development of sepsis 
syndrome were those with trauma [11.0 (9.1) 
days] and those with nosocomial respiratory tract 
infections [ 10.5 (9.4) days], significantly longer 
than for the other subsets (p<O.O1). Those 
undergoing the most surgical procedures before the 
development of sepsis syndrome were patients 
with trauma ( 8 2 . 5 % ,  RR = 2.59 ,  p<O.OOl), 
intraabdominal infections (73.1%, RR = 2.35, 
p<O.001), skin infections (53.1%, RR = 1.51, 
p<0.001) ,  and nosocomial respiratory tract 
infections (52.1%, RR = 1.5, p<O.OOl). 
Table 5 gives the incidence of sepsis syndrome, 
bacteremia, refractory shock, and complications 
(excluding refractory shock) in each patient 
population. The incidence of gram-negative 
bacteremia ranged from a low of 2.5% in patients 
with a nursing home-acquired respiratory tract 
infection to a high of 27.3% in those with a 
community-acquired urinary tract infection. The 
incidence of sepsis ranged from a low of 13.2% in 
patients with community-acquired urinary tract 
infections to a high of 39.4% in those with trauma 
and 40.6% in patients with gram-negative 
bacteremia mutually exclusive of other patient 
populations. 
The gram-negative isolates cultured from blood 
varied somewhat among the populations. 
Escherichia coli was the most frequently isolated in 
patients with community-acquired urinary tract 
infections (62.9%), nursing home-acquired urinary 
tract infections ( 5  7.5%), nursing home-acquired 
respiratory tract infections (50.0%), intraabdominal 
infections (36.6%), and gram-negative bacteremia 
(41.2%). Pseudornonas sp were isolated most 
frequently in patients with nosocomial respiratory 
tract infections (38.5%) and febrile patients with 
cancer (29.0%). Trauma patients were most likely 
to have Enterobacter sp isolated (33.3%), and 
patients with nosocomial urinary tract infections 
had a combination of gram-negative isolates (25%). 
Skin infections were most often attributable to a 
single gram-negative isolate (35.7%). 
The overall mortality rate ranged from 5.3% in 
patients with community-acquired urinary tract 
infections to 31.4% in patients with nosocomial 
respiratory tract infections. Patients with 
community-acquired urinary tract infections were 
at a reduced risk of mortality (RR = 0 . 3 3 ,  
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Table 4. Patient Demographics Stratified by High-Risk Populations 
Admitted to Onset of Sepsis Hospital 
Medical School- from Admission Duration Number of 
Patient No. of Age (yrs) Men Affiliated Hospital (days) (days) Comorbiditiesa Overall RR 
Population Patients Mean (SD) No. (%) Mean (SD) Mean (SD) Mean (SD) Mean (SD) of Morality" 
Neutropenic 
cancer 232 59.0 (16.4)" 11 5 (49.6) 171 (73.7) 10.2 (15.3) 15 7 (15 1)" 1.3 (0.6) 0.95 
Community- 
Nursing home- 
acquired UTI' 210 81 4 (8.5)d 78 (37.1)d 122 (58.1) 0.6 (3.0)" 11.8 (8.8)d 1.2 (1.0) 0.73 
Nursing home- 
acquired RTI' 243 80.9 (8.1)d 103 (42.4) 158 (65.0) 1.2 (2.8)d 12.3 (8.9)" 1.4 ( l , l )d  0.80 
Nosocomial UTI' 134 76.5 (7.0)d 61 (45.5) 84 (62.7) 20.3 (17.7)d 28 6 (21.1)d 1.5 (1 l)d 1.68 
Nosocomial RTI' 188 75.2 (7.2)'' 116 (61.7)d 133 (71.1) 12.4 (22.8) 30 7 (30 1.4 (1.06)d 2.52d 
Skin 128 61.5 (18.9)d 77 (60.6) 85 (66.4) 6.9 (10.3) 21.4 (18.8) 1.3 (1.07) 0.69 
Trauma 160 40.6 (18.3)d 110 (68.8) 142 (88.8)d 6 6 (13.2) 31.6 (21.1)d 0.4 (0.6)d 0.76 
Intraabdominal 
acquired UTI' 227 76.0 (7.5)'' 106 (46.7) 106 (46.7)" 1.3 (2.lOlL' 10.6 (7.6)" 1.3 (1.0) 0 33" 
infection 223 59.8 (17.8)d 120 (53.8) 147 (65.9) 8.6 (19.8) 21.7 (23.2) 1.0 (1.1) 1.25 
Gram-negative 
Overall 1754 67 (18.4) 889 (50.7) 1150 (65.6) 7.4 (14.6) 18 (17.9) 1.2 (1.0) 
RR = relative risk; UTI = urinary tract infection; RTI = respiratory tract infection. 
'Comorbidities include chronic obstructive pulmonary disease, congestive heart failure, stroke or cerebral hemorrhage, diabetes mellitus, hepatic 
disease, malignancy, renal disease, major bum, and history of alcoholism 
"Overall mortality compared w t h  the entire population. 
'Patients were restricted to those over age 65 years. 
dp<O.OO1, comparisons made with overall population 
bacteremia 165 58.4 78 (47.3) 106 (64.2) 9.2(13.7) 19.1 (19.5) 1.2 (1.0) 1.24 
p<O.OO l), whereas those with nosocomial urinary 
tract infections (RR = 1.68 ,  p=0.003)  and 
nosocomial respiratory tract infections (RR = 2.52, 
p<O.OO 1) were at a significantly increased risk of 
mortality 
As one would expect, mortality rates generally 
increase as one develops sepsis, shock, and 
complications. The mortality rate for patients with 
sepsis syndrome and refractory shock ranged from 
a low of 33.3% in trauma patients (RR = 0.58, 
p=0.016) to a high of 73.9% in febrile patients 
with cancer (RR = 1.44, p=0.004) and 71% in those 
with nosocomial respiratory tract infections (RR = 
1.40, p=0.037; Table 6). The types of complications, 
other than refractory shock, among patient groups 
was similar. 
Discussion 
This prospective surveillance study clearly 
demonstrates that the incidence of sepsis syndrome 
and associated morbidity and mortality varies 
depending on the population. The incidence of 
sepsis syndrome was 2 6 . 1 % ,  as expected, 
somewhat lower than that reported in sepsis 
clinical trials. lo-'' The difference in incidence can 
readily be explained by differences in study design 
as well as the seriousness of patients' conditions. 
Other clinical trials conducted at large centers 
attempted to enroll patients who met stringent 
criteria that were designed to identify sepsis.". l1 
In contrast, our study, in which 35% of hospitals 
were not affiliated with medical schools, was 
designed to monitor patients in whom antibiotics 
were initiated for suspected or documented gram- 
negative infection and who were at high risk for 
sepsis. Although other trials were designed to 
target patients who were septic, it is important to 
note that their incidence of sepsis was not 
100%.10-'2 In one, for example, the number of 
patients reported with gram-negative sepsis was 
only 68%, suggesting that the criteria in and of 
themselves are not predictive of gram-negative 
sepsis." Our prospective design allows for the 
calculation of incidence rates and the absolute 
difference in rates among groups (attributable 
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Table 5. Incidence of Specific Clinical Events Stratified by Risk Group (N = 1754) 
Complication 
Sepsis other than 
Sepsis Syndrome and Refractory Refractory 
Patient Population" No. (%Ih No.  (YO)' No. (%)L No. ("/)" No. (%)" No. (%)" 
Neutropenic cancer 232 (13.2) 31 (13.4) 43 (18.5)' 15 (34.9) 23 (53.9) 30 (69.8) 
Community-acquired UTI 227 (12.9) 62 (27.3) 30 (13.2)' 17 (56 7) 8 (26.7)' 16 (53.3) 
Nursing home-acquired UT1 210 (12.0) 40 (19 0) 62 (29.5) 24 (38.7) 16 (25.8)' 27 (43.6)' 
Nursing home-acquired RTI 243 (13.9) 6 (2.5) 57 (23.5) 5 (8.8) 20 (35.1) 26 (45.6)' 






134 (7.6) 12 (9.0) 31 (23.1) 4 (12.9) 13 (41.9) 17 (54.8). 
188 (10.7) 13 (6.9) 63 (33.5)' 8 (12.7) 31 (49.2) 42 (66.7) 
128 (7.3) 14 (10 9) 31 (24.2) 8 (25.8) 13 (41.9) 18 (58.1) 
160 (9.1) 21 (13.1) 63 (39.4)' 9 (14.3) 30 (47.6) 47 (74.6)' 
223 (12 7) 41 (18.4) 66 (29.6) 18 (27.3) 43 (65.2)' 52 (78.8)' 
Gram-negative bacteremia 165 (9.4) 67 (40.6)' 67 41 (61.2)' 44 (65.7) 
Overall 1754 (100) 389 (22.2) 457 (26.1) 164 (35.9) 216 (47.3) 286 (62.6) 
"Risk groups are not mutually exclusive except for the gram-negative bacteremia patient population, which includes only those who did not fit 
criteria for other populations listed. 
bUenominator = 1754. 
'Denominator = total number of patients in the population. 
'!Denominator = total number of patients in the population with sepsis syndrome 
'p<0.05. 
risks), as well as relative risks.13 Thus, the results 
are more appropriate to use when developing 
treatment strategies for broadly defined patient 
populations. 
Despite differences reported in the incidence of 
sepsis, the overall 28-day mortality in this study 
was 37.6%, and is strikingly similar to the 42% in 
several clinical Similarly, the published 
incidence of shock in patients with sepsis 
syndrome, 40%,14 is close to that in our study, 
47 .7%.  The similarity in  sepsis-associated 
morbidity and mortality between this study and 
other clinical trials suggests that misclassification 
bias was minimal and that our numbers are 
representative of the outcomes due to this disease 
process. Mortality rates clearly change depending 
on the definition of sepsis. Applying the new 
definitions using the patients in this data base, 
94% had systemic inflammatory response 
syndrome with a mortality rate of 15.2%, and 
(39.2%) had severe sepsis with a mortality rate of 
28.2%.9. 
The incidence of gram-negative bacteremia in 
patients with sepsis syndrome in this study 
(35.9%) was virtually identical to that observed by 
others (37%)" and clearly demonstrates that 
positive blood cultures develop in a minority of 
patients. Of importance, 225 (57.8%) patients had 
positive blood cultures but did not have signs and 
symptoms of sepsis. Similar to previous studies, 
these data underscore the limitation in using the 
results of blood cultures as the sole criterion for 
sepsis syndrome. Approximately one-third of 
patients with the syndrome will have positive 
blood cultures, and over half of the patients with 
positive blood cultures do not have sepsis 
syndrome. 
The incidence of sepsis syndrome and its 
sequelae varied widely across the different 
populations in this data base. Elderly patients with 
nosocomial respiratory tract infections had the 
highest risk for death, 57.1% (RR = 1.66, p<0.05). 
Other groups identified nosocomial pneumonia as 
the leading infectious cause of death as well as the 
leading cause of nosocomial-associated mortality.l5% 
l6 Conversely, patients with community-acquired 
urinary tract infections and sepsis syndrome had 
the lowest risk for death, 20% (RR = 0.51, p<0.05), 
confirming a recent report that patients with 
urinary tract infections have significantly lower 
mortality than those with the syndrome due to 
other causes." 
Although the mortality rate for patients with 
trauma was relatively low, 20%, the incidence of 
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Table 6 .  Mortality Rates for Clinical Events Stratified by Patient Population 
Mortality 
Sepsis Syndrome and 
Sepsis Syndrome Refractory Shock 
Patient Population No. ( O h ) *  R R ~  No. (%)a R R ~  
Neutropenic cancer 24 (55.8) 1.56' 17 (73.9) 1.44' 
Community UTI 6 (20) 0.51' 4 (50) 0.93 
Nursing home UTI 15 (24.2) 0.61' 7 (43.8) 0.80 
Nursing home RTI 17 (29.8) 0.77 9 (45.0) 0.82 
Nosocomial RTI 36 (57.1) 1 .66  22 (71.0) 1.40' 
Trauma 13 (20.6) 0.51' 10 (33 3) 0.58' 
Abdominal 30 (45.5) 1.25 28 (65.1) 1.28 
Gram-negative bacteremia 23 (34.3) 0.90 17 (41.5) 0.73 
Overall 172 (37.6) 116 (53.7) 
'Denominator = number of patients in the population. 
hRR = Relative risk computed as incidence in patient populatiodincidence in all other populations. 
'p<O 05 
Nosocomial UTI 15 (51.6) 1.4 7 (53.8) 1.0 
Skin 11 (35.5) 0.94 7 (53.8) 1.0 
sepsis syndrome was high, 39.4% (RR = 1.59, 
p<0.05). This indicates that the incidence of sepsis 
syndrome does not parallel mortality. The low rate 
of mortality in trauma patients may be explained 
by the fact that these patients were younger (mean 
age 40 yrs) and had fewer (< 10%) comorbidities 
than other populations. In addition, they were 
monitored aggressively in specialized university 
hospital trauma centers. 
Overall, the marked disparity in the incidence of 
sepsis syndrome versus mortality rate raises several 
issues. The first is to identify patients who should 
be targeted to receive therapies specific for sepsis 
syndrome. The second is to establish the 
appropriate end point for patient monitoring of 
outcomes. Given the fact that the elderly have 
fewer complications and shorter ICU stays, one 
would expect their mortality to be lower, however, 
the rate is similar across age groups. This may 
suggest that morbidity might be an alternative end 
point to mortality in clinical trials of agents that 
prevent or modulate the systemic inflammatory 
response. Elderly patients with sepsis syndrome 
did not use more medical resources, as measured 
by length of ICU stay and complication rates. Most 
resources went to younger patients age 18-59 
years, 50% of whom were in the ICU more than 9 
days. Thus, perhaps innovative therapies would be 
wisely administered in this group potentially to 
reduce ICU stay and costs of treating complications. 
As mentioned, our study differed from previous 
clinical trials in a number of important aspects. 
First, overall 47 .8% of patients with sepsis 
syndrome were women, compared with 34.5% and 
41.5% in other trials.", l 2  The preponderance of 
men in those trials may have been attributed to the 
exclusion of women of childbearing age. On 
further analysis, however, only 41% of the patients 
in our study were women under 50 years of age, 
which would support  the fact that men are 
predominantly at risk for s e p ~ i s . ' ~ , ' ~  Second, 
severely neutropenic patients were excluded from 
other trials,20 and therefore the results should not 
be extrapolated to the general population of 
patients with sepsis syndrome. Third, our study 
shows that large numbers of patients are in fact at 
low risk for developing the syndrome and its 
sequelae; therefore they may not be candidates for 
any innovative therapies of the kind given in the 
clinical trials. 
Our study did have some limitations. Sepsis 
syndrome was used as an end point, and mortality 
rate varies depending on the definition of sepsis. 
This also makes it difficult to compare results of 
this surveillance study with those of clinical trials 
due to different criteria for sepsis. Because our 
study required that subjects have suspected or 
documented gram-negative infection and have 
initiated antibiotic coverage at study entry, the 
patient populations were clearly skewed toward 
those with gram-negative infections. Finally, 
because of economic and time constraints, we 
focused on a sample of patients at high risk of 
developing sepsis. 
The impressive variability in the incidence of 
sepsis syndrome and its associated sequelae among 
different populations strongly suggests that sepsis 
treatment goals and algorithms have to be based in 
part on the targeted population, and that clinical 
trials must stratify patients among the various risk 
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populations. Theoretically, treatment approaches 
as well as efficacy may be quite different across 
patient risk groups. For example, our results 
suggest that patients with community-acquired 
urinary tract infections, because of their low 
incidence of complications and mortality, may 
require short-term supportive care outside the 
ICU, and may be discharged early taking oral 
antibiotics, thus conserving hospital resources for 
high-risk patients. These data also have implications 
for researchers designing clinical trials. Because 
elderly patients with community-acquired urinary 
tract infections are at such low risk, perhaps they 
should not be included in clinical trials of new 
agents designed to modulate the various 
inflammatory mediators responsible for the 
pathogenesis of sepsis, In addition, the rate of 
complications should be applied in conjunction 
with mortality when testing the efficacy of 
innovative treatment agents for the pathogenesis of 
sepsis syndrome. 
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